ReviewFrontiers in immunology2018
Intriguing Relationships Between Cancer and Systemic Sclerosis: Role of the Immune System and Other Contributors.
Review in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 93 citations in OpenAlex.
- Article
- Lung cancer in patients with scleroderma-associated interstitial lung disease: Case series and implications for screening.Respiratory medicine case reports · 2026Article
- Change in Antinuclear Antibodies After Lung Transplantation in Patients with Systemic Sclerosis.Journal of clinical medicine · 2025Article
- Cancer Risk in Patients With Systemic Sclerosis: A Nationwide Cohort Study in South Korea 2004 to 2021.Arthritis care & research · 2025Article
- Paraneoplastic systemic sclerosis: A distinct entity or a mere association - A case report.Journal of family medicine and primary care · 2025Article
- Article
- Neoplasm related mortality risk in Systemic Sclerosis: a nationwide study.BMC rheumatology · 2025Article
- Intravascular Large B-Cell Lymphoma Presenting as Systemic Capillary Leak Syndrome With Immunological Phenomena: A Case Report.Case reports in hematology · 2025Article
- Leveraging immune checkpoint inhibitors in lung cancer patients with pre-existing autoimmune disease: clinical insights, optimal timing, and predictive biomarkers for optimal treatment outcomes.Frontiers in immunology · 2025Review
- Evaluation of malignancy risk in patients with SSc by autoantibody profile: a systematic review with meta-analysis.Rheumatology advances in practice · 2025Review
- Observational
- Case report: Systemic sclerosis during neoadjuvant therapy for breast cancer in a 59-year-old woman.Frontiers in immunology · 2024Review
- Journey into the Esophageal Complications: Decoding Systemic Sclerosis with Cutting-Edge Endoscopy, Manometry, and Ambulatory pH-Study.International journal of general medicine · 2024Article
- Serum IL-17 and TNFα as prognostic biomarkers in systemic sclerosis patients: a prospective study.Rheumatology international · 2024Article
- Critical digital ischaemia in systemic sclerosis exacerbated by multiple myeloma: A case report.Journal of scleroderma and related disorders · 2023Article
- Article
- Current Concepts on the Pathogenesis of Systemic Sclerosis.Clinical reviews in allergy & immunology · 2023Review
- Autoantibodies against PIP4K2B and AKT3 Are Associated with Skin and Lung Fibrosis in Patients with Systemic Sclerosis.International journal of molecular sciences · 2023Article
- Malignancies in systemic rheumatic diseases: A mini review.Frontiers in immunology · 2023Review
- Molecular Pathways of Breast Cancer in Systemic Sclerosis: Exploratory Immunohistochemical Analysis from the Sclero-Breast Study.Journal of personalized medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic sclerosis (SSc) is an autoimmune connective tissue disorder, characterized by multisystem involvement, vasculopathy, and fibrosis. An increased risk of malignancy is observed in SSc (including breast and lung cancers), and in a subgroup of patients with specific autoantibodies (i.e., anti-RNA polymerase III and related autoantibodies), SSc could be a paraneoplastic syndrome and might be directly related to an immune response against cancer. Herein, we reviewed the literature, focusing on the most recent articles, and shed light onto the potential relationship between cancer and scleroderma regarding temporal and immunological dimensions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.